Failures of once-a-week trimethoprim-sulfamethoxazole prophylaxis in children undergoing allogeneic hematopoietic stem cell transplant.
Elio CastagnolaAlessio MesiniCarolina SaffiotiAndrea MoscatelliFilomena PierriStefano GiardinoMaura FaraciPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
Once-a-week cotrimoxazole is an effective prophylaxis for pneumocystosis during antineoplastic chemotherapy or autologous stem cell transplant. Following allogeneic stem cell transplant, this schedule is at risk of pneumocystosis or neurotoxoplasmosis, as demonstrated by these case reports. Therefore, a 3-times-a-week schedule must be adopted in these patients.
Keyphrases
- hematopoietic stem cell
- stem cells
- stem cell transplantation
- bone marrow
- end stage renal disease
- newly diagnosed
- ejection fraction
- cell therapy
- young adults
- peritoneal dialysis
- prognostic factors
- placebo controlled
- clinical trial
- radiation therapy
- squamous cell carcinoma
- locally advanced
- high dose
- mesenchymal stem cells
- rectal cancer
- chemotherapy induced